Role of Bone Sialoproteins in Osseous Metastasis of Breast Cancer
Final rept. 1 Jul 1996-30 Sep 1999
GEORGETOWN UNIV WASHINGTON DC
Pagination or Media Count:
Recently, antibodies to the growth factor receptor ErbB2 have been established as a valid therapeutic approach in the treatment of breast cancer. Because breast cancers can express a number of growth factor receptors the evaluation of antibodies targeting other growth factor receptors implicated in the progression of breast cancer is extremely important. We have explored the potential of blocking antibodies targeting the insulin- like growth factor 1 receptor IGF1R to inhibit the growth of breast cancer cells using an in vitro model. Limited dilution cloning of T47DA18 cells in estrogen free media generated the panel of T47DC4nW clones. These cell lines were originally estrogen receptor negative. We assessed the status of ER and IGFlR in these cells lines and found them to be a useful model to determine the effects of IGFlR blocking antibodies.
- Anatomy and Physiology
- Medicine and Medical Research